CREB1 and breast cancer: One study shows that docetaxel, a commonly used chemotherapeutic drug for breast cancer, can trigger the CCL3-CCR5-p38 pathway by downregulating CREB via reactive oxygen species accumulation in both breast tumor cells and macrophages, ultimately mediating tumor cell phagocytosis by macrophages (Sheng et al, 2022).